AAP guidance ‘another reason to believe’ in GeneDx, says Craig-Hallum

Craig-Hallum analyst Bill Bonello recommends buying shares of GeneDx (WGS), even after the 19% jump on the American Academy of Pediatrics news on Monday afternoon, the analyst tells investors in a research note. The firm, which has a Buy rating and $114 price target on the shares, expects exome and genome testing to become the standard of care for pediatric rare diseases over time, and says the AAP guidance is another reason to believe.